Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance
暂无分享,去创建一个
Yves Moreau | Tomi Silander | Anne-Mieke Vandamme | Ricardo Camacho | Kristel Van Laethem | Koen Deforche | Zehava Grossman | M. A. Soares | R. Kantor | Deforche K | Silander T | Camacho R | Grossman Z | Soares Ma | Van Laethem K | R F Kantor | Y. Moreau | Vandamme A-M | B. Workgroup
[1] Michael I. Jordan. Learning in Graphical Models , 1999, NATO ASI Series.
[2] A. Rachlis,et al. Antiviral therapy. , 1989, Clinics in dermatology.
[3] Luís Torgo,et al. Knowledge Discovery in Databases: PKDD 2005, 9th European Conference on Principles and Practice of Knowledge Discovery in Databases, Porto, Portugal, October 3-7, 2005, Proceedings , 2005, PKDD.
[4] Thomas Lengauer,et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. , 2005, The Journal of infectious diseases.
[5] David Heckerman,et al. A Tutorial on Learning with Bayesian Networks , 1999, Innovations in Bayesian Networks.
[6] R. Samudrala,et al. Simple Linear Model Provides Highly Accurate Genotypic Predictions of HIV-1 Drug Resistance , 2003, Antiviral therapy.
[7] Judea Pearl,et al. Graphical Models for Probabilistic and Causal Reasoning , 1997, The Computer Science and Engineering Handbook.
[8] Anne-Mieke Vandamme,et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G , 2005, AIDS.
[9] Lynn Morris,et al. Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.
[10] Rami Kantor,et al. Drug resistance in non-subtype B HIV-1. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[11] Marcelo A. Soares,et al. Impact of Nelfinavir Resistance Mutations on In Vitro Phenotype, Fitness, and Replication Capacity of Human Immunodeficiency Virus Type 1 with Subtype B and C Proteases , 2004, Antimicrobial Agents and Chemotherapy.
[12] A. Vandamme,et al. A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients , 2001, Antiviral therapy.
[13] D. Brutlag,et al. Discovering structural correlations in α‐helices , 1994 .
[14] Matthew J. Gonzales,et al. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs , 2001, Nucleic Acids Res..
[15] Robert W. Shafer,et al. Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.
[16] Dan Engelhard,et al. Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir , 2004, Antimicrobial Agents and Chemotherapy.
[17] Thomas Lengauer,et al. Learning multiple evolutionary pathways from cross-sectional data , 2004, J. Comput. Biol..
[18] Thomas Lengauer,et al. Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking , 2005, PKDD.
[19] Tulio de Oliveira,et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..
[20] Thomas D. Wu,et al. Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.
[21] Nir Friedman,et al. Data Analysis with Bayesian Networks: A Bootstrap Approach , 1999, UAI.